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EDITORIAL REVIEW
Polymorphisms of the renin-angiotensin system genes in
progressive renal diseases
If a mutation, such as deletion of a large autosome, occurs in
the human genome, the affected fetus is spontaneously aborted,
and the mutation cannot be passed on to the offspring. However,
if the effect of mutation is not deleterious, those with it can
survive, and it can be readily transmitted from generation after
generation, disseminating into the gene pooi of a large popula-
tion, causing no or only minor inconvenience. The phenomenon
of having two or more genetic variants is called polymorphism. In
practice, a genetic locus is considered polymorphic if the rarest
allele has a frequency of  1%. At such a frequency, the rarest
allele could not be maintained by recurrent mutation alone [1].
DNA polymorphism is known to exist for the great majority, if not
all, of human genes. While, until recently, genetic disorders had
been considered primarily in the context of simple Mendelian, or
single-gene disorders (such as polycystic kidney disease), many
human diseases are now recognized as an endpoint resulting from
the complex interaction of multiple environmental factors and
inherited genes (that is, susceptibility alleles) which convey sus-
ceptibility with each having a minor, but additive, impact. Studies
have shown that some gene changes, previously considered to be
harmless or silent, affect their gene products and play a significant
role in the development and advancement of certain diseases.
It is now known that DNA polymorphism can affect the
susceptibility to common diseases, such as diabetes mellitus,
essential hypertension, osteoporosis, Alzheimer disease, and sev-
eral types of neoplasm [reviewed in 2]. Also, it has been suggested
that some gene variants contribute to differences in vulnerability
to alcoholism and substance abuse [reviewed in 31. Since each
polymorphism has only a small individual impact on the pheno-
type, identification of individual genes contributing to a particular
disease state is more challenging than major chromosomal abnor-
malities or single gene mutations. Even the presence of a full
complement of postulated susceptibility alleles at multiple loci
does not necessarily lead to overt disease, thus insulin-dependent
diabetes mellitus often occurs in only one of identical twins
because subtle differences in exposure to environmental agents
play a role in the pathogenesis [4, 5]. On the other hand, since
polymerase chain reaction (PCR) amplification and multiple
patients' blood samples are the only requirement to study such
genetic contribution, research interest in, and understanding of,
gene polymorphisms have exploded over the last few years. Thus,
DNA samples from patients with a variety of disease entities have
been genotyped with the goal to identify new genetic risk factors.
Since accurate characterization of patients and careful definition
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of the clinical phenotype are essential for successful identification
of genetic markers for disease susceptibility, studies examining
phenotype-genotype correlations clearly belong in the arena of
clinical investigation.
Indeed, although the methodology was more cumbersome,
genetic variabilities have been linked to renal diseases. A signifi-
cant genetic component of immunopathology was localized to
variations in the major immunohistocompatibility complex with-
out defining the physical nature of the variations: HLA-DR2 and
HLA-3 were associated with membranous nephropathy [6—9],
while DR-i and HLA-B35 were more often observed in patients
with IgA nephropathy, the latter portending particularly poor
prognosis [101. Gene variations in the complement system have
also been associated with occurrence of IgA nephropathy [11, 12].
Recently, polymorphism of TAP (transporter associated with
antigen processing), which affects antigen presentation, has been
described [7, 13]. The TAP1 variation was observed to be signif-
icantly more frequent in patients with idiopathic membranous
nephropathy [14]. Moreover, while the study reaffirmed an earlier
association between HLA-DR3 and membranous nephropathy,
the two genetic variables were not in linkage disequilibrium
indicating they are independent and not synergistic.
Variations in the severity of disease has been linked to poly-
morphisms in several proinflammatory cytokines such as TNF-a
and TNF-f3 and interleukins which have been linked to the
occurrence and severity of clinical manifestations in many inflam-
matory disorders [15—18]. It is of interest that not only do these
cytokines modulate the severity of non-specific and antigen-
specific tissue damage, but they also can amplify MHC class II
antigen expression leading to autoimmunity [19]. Thus, TNF-f3
gene polymorphism, which has been linked to altered cytokine
production, has been shown in patients with IgA nephropathy,
idiopathic membranous nephropathy and insulin-dependent dia-
betes mellitus, while polymorphisms in TNF-a in a region that
controls transcription, affects the severity of systemic lupus ery-
thematosus [18, 19]. Overall, polymorphisms of some proinflam-
matory cytokine genes can affect the severity of disease.
Parallelism in the role of angiotensin in cardiovascular versus
renal remodeling
Angiotensin 11 (Ang II), an octapeptide, is a key biological
factor not only in vascular physiology hut also pathology of the
vascular organs. Its synthesis involves several precursor peptide
and enzyme proteins that are derived from separate genes (Fig.
1). Polymorphisms have been reported for several of these genes.
In parallel to the evolution of our knowledge of the function of
Ang II, the genetic role of the renin-angiotensin system (RAS)
was first considered in hypertension. The angiotensinogen, ACE
and angiotensin receptor genes have long been considered as
candidate genes, the variants of which contribute to essential
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hypertension [20, 21]. Ang II, the biologically active product of
RAS, regulates blood pressure by acting on several types of cells,
which have remarkably diverse functions. Ang II not only has a
potent constrictory action on vascular smooth muscle cells, but
also has a dipsogenic action through acting on neuronal cells. Ang
II can stimulate fluid retention by acting directly on tubule cells,
or more indirectly, through stimulating aldosterone release from
the adrenals.
A discovery of yet another potent action of Ang II, that is, a
growth factor-like effect on vascular-type cells, triggered a recent
surge of research interest in the possible contribution of RAS
genes to other disease entities, namely cardiac ischemia, cardiac
hypertrophy and progressive renal failure. By inspecting the
biology of RAS closely in these settings, one may be immensely
impressed by the parallelism of our understanding of Ang II
actions on the heart versus the kidney (Fig. 2). Thus, earlier, the
tissue protective effect of pharmacological inhibition of RAS in
injuries of the heart and the kidney was attributed solely to the
antihypertensive effect of agents. However, the salutary effect of
Ang inhibition with ACE inhibitors (ACEi) in both heart and
kidneys was subsequently shown to be independent of systemic
blood pressure [22—251. Since ACEi is not only an arterial
vasodilator but also a venodilator, ACEi's unique cardioprotective
role was attributed in part to its preload-reducing capacity 1261.
Similarly, the unique renoprotective effect of ACEi has also been
attributed to its potent ciferent arteriolar dilative effect, which
results in a profound fall in glomerular pressure [271. Of interest,
direct measurements of ventricular pressures in several animal
models of left ventricular hypertrophy has led to the conclusion
that pressure within the ventricle is also not a determinant of
ventricular hypertrophy or collagen deposition in the myocardium
[281. Likewise, glomerular pressure measurements in several
animal models revealed that the pressure within the glomerular
capillary does not always correlate tightly with the degree of tissue
injury [29, 30].
To obtain alternative explanations for the organ protective
effect of ACEi, investigators in both cardiology and nephrology
searched for other biological actions of Ang II. Subsequent
studies revealed that Ang 11 in vitro promotes hypertrophy and
Fig. 2. Parallelism of the tissue-injurious effects of angiotensin on the heart
and the kidney. Studies on the role of the renin angiotensin system in tissue
remodeling of these two major vascular organs increasingly recognize
angiotensin's local actions to induce cell growth and collagen accumula-
tion as pathophysiologically important maladaptive processes shared by
these organs, which arc turned on after injury and contribute to progres-
sive organ failure.
expression of immediate early genes, such as c-fbs, and growth
factors, including TGF-13 and PDGF in cardiomyocytes, vascular
smooth muscle cells, glomerular mesangial cells and renal proxi-
mal tubule cells (Fig. 2) [31—40]. They collectively promote
accumulation of collagens both by activating synthesis, and inhib-
iting degradation, of collagens [36, 38, 39, 41—45]. In connection
with the latter, there is accumulating evidence that RAS promotes
Angiotensin II AT1, AT2, AT receptors
Phenotypes
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Fig. 1. Essential components of the renin-
angiotensin system. In this diagram, chymase,
cathepsin G and other enzymes potentially
involved in the cleavage of angiotensin
molecules are not included.
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plasminogen activator inhibitor (PAl-i) [46—51]. PAl-i has been
associated with thromboembolic events and, by interfering with
the fibrinolytic processes, may contribute to the risk of re-stenosis
in patients with a history of myocardial infarction [46, 47]. Thus,
increased activity of ACE can, by activating PAl-i, predispose to
pathological processes in cardiac and renal tissues. Most recently,
aldosterone has been proposed to be a part of the intermediary
mechanisms for collagen deposition and fibrosis in both heart and
kidneys [52, 53]. Besides, importance of the local RAS has been
recently emphasized for tissue remodeling processes in both these
organs. The functional significance of locally synthesized Ang II is
still feverishly debated [154, 155]. It is likely that Ang II is
generated largely by the endothelium 1561, locally or otherwise,
which then, by acting on cardiomyocytes and fibroblasts in the
heart and mesangial and tubulointerstitial cells in the kidney,
promotes hypertrophy and collagen accumulation in these organs
(Fig. 2). Functionally, Ang IT-induced changes in the heart can
lead to congestive heart failure, myocardial ischemia and, poten-
tially, restenosis of the coronary artery following angioplasty. In
these processes, while accumulation of collagen will decrease
cardiac contractility, the hypertrophy of myocardial tissue will
increase oxygen demand and increase the risk of myocardial
ischemia. Ang II may also induce neointimal proliferation, which
leads to obliteration of vessels [57]. With regards to the kidney,
uremia is the common functional end-point of these Ang II
injuries. The parallelism of the pathophysiologic actions of Ang II
on the heart versus the kidney is further underscored by the series
of recent discoveries that physical forces imposed on cultured
cardiac myocytes and glomerular cells activate the local RAS in
remarkably similar manner [58—60].
Given the cardio- and renoprotective effects of ACE inhibitors
observed independently of their antihypertensive effect in many
clinical trials, it seems natural that cardiac hypertrophy, myocar-
dial ischemia and progressive renal diseases have been studied as
settings where variance in RAS genes may play a significant role
for disease progression independently of blood pressure.
Polymorphism of renin-angiotensin system genes in
hypertension and cardiovascular diseases
Angiotensin I converting enzyme or kininase II, also called
dipeptidyl-carboxypeptidase I, is a zinc metallopeptidase widely
distributed on the surface of endothelial and epithelial cells. The
human ACE gene is located on chromosome 17q23, spans 21 kb,
and includes 26 exons. Its coding sequence is 4.3 kb in length and
codes for a 1306 amino-acid protein, including a signal peptide of
29 residues. ACE is composed of 2 homologous domains with two
active sites. Rigat et al [61] identified a polymorphism within
intron 16 consisting of the presence or absence of a 287 base pair
fragment (Fig. 3). The presence of the fragment defines the
insertion or the I allele, while its absence defines the deletion or
the D allele. The ACE genotype was thus classified as II, ID, or
DD. In Caucasian subjects, the mean ACE levels in DD individ-
uals was about twice that found in II individuals, with ID's having
intermediate levels, indicating that the ACE polymorphism is
co-dominant (that is, the effects of both alleles are detectable in
the heterozygote). The ACE polymorphism has a significant
association not only with the plasma level of ACE, but also with
the intracellular ACE as measured by ACE activity in T-lympho-
cytes [62].
A DNA sequence analysis of both I and D alleles of the ACE
gene in our laboratory [63] revealed a pair of identical 14-base
DNA sequences, with the first on one end of the insert and a
repeat which flanks the opposite end of the insert (Fig. 4). The
arrangement of these two repeats suggests a possible origin of the
D allele. During meiosis, one of these two repeats may have
aligned with the complement of the other, producing a 'loop-out'
of the intervening 287 bp fragment (Fig. 4). This polymorphic
pattern suggests that the nature of the mutational event may have
been deletion, not insertion. Continued DNA synthesis would
have then taken place on the shorter template strand.
Cambien et al [641 first proposed that the lID polymorphism is
a marker for increased risk of myocardial infarction (MI). Men
with the DD genotype were found to have 1.34 times the risk for
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Fig. 4. Speculative mechanism of the mutation event that occurred at the
ACE lID locus. A pair of identical 14-base DNA sequences exists on the I
allele. The first on one end of the insert and a repeat flanks the opposite
end and immediately follows the insert. During meiosis, one of these two
repeats could align with the complement of the other, thus producing a
'loop-out' of the intervening 287 bp fragment.
MI when compared to those with other genotypes. The risk was
independent of other known prognosticators, including plasma
lipids, fibrinogen, body mass index, cigarette smoking or hyper-
tension. Moreover, this odds ratio increased further to 3.2 in a
subgroup of low risk individuals defined by favorable lipid profile
and body mass index.
Similar findings have been reported by several subsequent
studies [65, 66] while others showed variant results [67—69]. For
example, Bohn et al found an increase in the I allele in patients
with MI [67]. However, they also found a positive association of
parental history of MI with the D allele, and suggested a
co-dominant effect of the D allele for increased risk of MI [701.
This study reiterated a positive association of the D allele with
parental history of MI found by Tiret et al [66]. The caveat from
these studies is a potential involvement of an artifact in determin-
ing the frequency of the D allele in patient populations that are at
risk of fatal cardiovascular disease. Thus, aside from more general
pitfalls of genetic markers discussed below, it is possible that the
D allele disappears preferentially from a subject group as a result
of premature deaths from cardiovascular events. In this regard,
Cambien's original report was based on patients who were
recruited into the study 3 to 9 months after sustaining an episode
of Ml. Indeed, one study of autopsies from individuals dying from
MI or sudden cardiac death found a higher frequency of the D
allele than in controls [66]. By contrast, in a prospective study on
male U.S. physicians, Lindpaintner et al did not find the ACE
genotype to be predictive of either MI or ischemic heart disease.
In the latter, the overall incidence of cardiovascular events,
however, was substantially lower than expected. The authors
stated that the genetic background (that is, influence from other
genes) of the North American population is likely to he more
ethnically diverse than European or Japanese cohorts, which may
have dampened the impact of ACE lID polymorphism.
Interaction between genes in affecting cardiovascular disease
was shown by Bonnardeaux et al, who found a synergistic effect of
ACE lID polymorphism and angiotensin II type 1 receptor gene
polymorphism [71] on the risk for MI [70]. Of the two established
Ang II receptors, that is, AT1 and AT2, AT1 conveys most of the
known actions of Ang II. The ATI gene consists of at least four
exons and is localized to chromosome 3 in the human [71]. The
polymorphism studied by Tiret consists of a nucleic acid substitu-
tion of A to C at position 1166 (A1166C) on the 3' untranslated
region of an AT1 exon [62]. A1166C homozygosity, which was by
itself not predictive of MI, did, in a synergistic fashion with the
ACE gene DD genotype, associate with increased risk of MI. This
association was particularly strong in individuals without other
known risk factors. Since this A to C substitution does not alter a
potential mRNA polyadenylation or destabilization signal, this
polymorphic locus is believed to be a marker for an adjacent
functional variant locus.
In another study [72], patients were grouped by the degree of
coronary artery stenosis and the occurrence of MI. Individuals
with greater than 60% stenosis of their coronary arteries were
found to have similar l/D genotype distributions as patients with
less than 10% stenosis. However, among patients with the more
severe stenosis, the incidence of MI was significantly associated
with the D allele. Similar results were obtained in individuals
sustaining a stroke [73]. Thus, some studies found an association
between the ACE genotype and lacunar stroke, but not cerebro-
vascular disease due to large vessel stenosis. Overall, once signif-
icant vascular stenosis occurs regardless of the triggering factors,
the ACE DD genotype appears to prime toward secondary
occlusive events.
The DD genotype has also been associated with hypertrophic
cardiomyopathy. Marian et al reported increased DD genotype in
individuals with hypertrophic cardiomyopathies compared with
their normal relatives [74]. An even higher frequency of the D
allele was found in another study of patients with hypertrophic
cardiomyopathy who had a strong family history of sudden death
[65]. Schunkert et al showed a positive association between the D
allele and cardiac hypertrophy in males but not in females [75].
This association was particularly strong in men without hyperten-
sion and led the authors to postulate that the DD genotype is an
independent risk factor, being particularly strong when no other
causative factors (such as left ventricular overload) are present.
Using more sensitive echocardiography to detect ventricular
hypertrophy, Ohishi, Rakugi and Ogihara reiterated these find-
ings [76]. Interestingly, these authors observed that normotensives
with the DD genotype had even higher left ventricular mass index
than hypertensives with the DD genotype [76]. Other forms of
cardiovascular pathology associated with the ACE l/D polymor-
phism include idiopathic dilated cardiomyopathy and idiopathic
ischemic cardiomyopathy [65]. Of note, in the absence of heart
disease, ACE gene polymorphism does not predict left ventricular
mass or function [77, 78j. This suggests that the impact of ACE
polymorphism may he too subtle to initiate, but still significant to
promote and accelerate, injury once the defense line is broken.
'Essential' hypertension does not follow a simple Mendelian
inheritance. Genetic variations in several RAS genes have been
evaluated for potential association with hypertension. However,
the ACE [79], renin [801 and AT1 receptor genes [711 have
I
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heretofore failed to be consistently linked or associated with
hypertension. On the other hand, Jeunemaitre et a! showed that
variation in the angiotensinogen gene is linked to hypertension
[811. The mutation in which threonine (T) is substituted for
methionine (M) at residue 235 was significantly more frequent in
hypertensives than in controls in two genetically distinct popula-
tions in Salt Lake City and Paris. The prevalence of the T variant
was 36% in control, 47% in unrelated index cases, and 51% in the
severely hypertensive individuals [81]. Moreover, T allele homozy-
gotes had —20% higher levels of plasma angiotensinogen. Al-
though no difference in the kinetics of the renin reaction has been
found when threonine was substituted for methionine at residue
235 in experiments of transient expression in mammalian cells,
higher plasma concentrations of angiotensinogen were observed
in individuals with the M235T variant than in siblings without this
variant [811. The correlation between plasma angiotensinogen and
blood pressure had already been noted [821. More direct support
that angiotensinogen gene modulates angiotensinogen levels and
hypertension comes from the transgenic mouse studies of Kim et
a!, who showed that the number of copies of angiotensinogen gene
correlates with both the levels of the peptide and systemic blood
pressure [781. Taken together, these studies suggest that angio-
tensinogen is important in human hypertension.
Interestingly, pre-eclampsia which has been noted to have
familial aggregation, but has not been regarded to be related to
essential hypertension, has also been found to have a significant
association with the M235T variant of the angiotensinogen gene
in Caucasian and Japanese women [84]. Other studies [85] have
also found co-segregation of a marker in the 3' flanking region of
the angiotensinogen gene with pre-eclampsia. These studies fur-
ther support the idea that a DNA sequence at or near the
angiotensinogen locus affect blood pressure.
These observations are of particular interest since early studies
suggested that plasma concentration of angiotensinogen far ex-
ceeds the Michaelis constant for the enzymatic reaction with
renin, implying renin as the rate limiting step in the activity of
RAS [86, 871. However, subsequent studies demonstrated that
plasma angiotensinogen level is close to the Km of the renin
reaction [88, 891. It is currently unclear whether the M235T
variant affects function, or serves as a marker for a distant
functional variant locus. It is of interest that other variants have
been defined and have been shown to alter renin kinetics. Some
variants augment the renin catalytic efficiency [85]. It is possible,
therefore, that in addition to common variants such as M235T,
which imparts some increased risk for hypertension, other 'pri-
vate' variants lead to predispositions that then determine individ-
ual differences in the course and severity of hypertension [81].
ACE gene polymorphism in renal diseases
The significance of ACE gene polymorphism varies among
different organs or tissues, depending on the local availability of
Ang I for conversion to Ang 11 by ACE. It has been shown that the
Ang Il/Ang I ratio is markedly high in the kidney; this ratio
averaged 0.3 and 2.0 in the plasma and kidney, respectively [901.
It is possible that the ACE l/D polymorphism may be particularly
relevant at the renal tissue level, such that renal tissue injury is
under a greater modulatory influence by the ACE l/D polymor-
phism, when compared to its influence on blood pressure or other
organs.
IgA nephropathy is recognized as the most common form of
glomerulonephritis in various parts of the world. Prognosis is
poorer than initially predicted, and nearly half of patients end up
with chronic renal failure. Abnormalities in IgA metabolism,
presumably as a result of chronic exposure to yet-to-be-defined
environmental antigens, are likely involved in the incidence of IgA
nephropathy [91, 921. The important risk factors for renal failure
currently known include severe proteinuria, impaired renal func-
tion and hypertension at the time of presentation [931. Since these
risk factors are common to practically all forms of chronic renal
disease, it is suggested that several key pathophysiological mech-
anisms independent of the pathogenesis of IgA nephropathyperse
may operate in the progression of IgA nephropathy. Locally
increased Ang II activity has been suggested to affect the progres-
sion of IgA nephropathy Moreover, several studies have
shown that ACE inhibitor effectively reduces proteinuria and/or
attenuates progressive decline in renal function even in normo-
tensive IgA nephropathy. The progressive process of IgA ne-
phropathy may, therefore, be modulated in part by the renin-
angiotensin system.
Several recent studies have shown a significant association in
IgA nephropathy between ACE gene polymorphism and the
progression to chronic renal failure. Our study of 53 Japanese
patients with IgA nephropathy showed that the frequency distri-
bution of ACE genotype is significantly different between patients
with versus without progressive decline in creatinine clearance
rate [95]. Whereas the frequency of ACE DD genotype in patients
with stable renal function (16%) was not significantly different
from that in the general Japanese population (—10%), the ACE
DD genotype in patients with declining renal function was signif-
icantly more frequent (43%). The relative risk of progression in
patients carrying the DD genotype was calculated to he nearly
four-fold of that in patients with other genotypes. A similar
conclusion was reached earlier by Yorioka et al [96] in a study of
48 Japanese patients with IgA nephropathy. In their comparison,
the rate of reduction in GFR of patients with DD or ID genotype
was significantly higher than those with II. Moreover, renal biopsy
specimens revealed significantly greater percentage of glomeruli
with sclerosis or segmental lesions in patients with DD or ID than
those with II.
Of importance, studies in other parts of the world revealed that
this significant correlation between the risk of progression and the
ACE I/D genotype crosses geographical and racial boundaries.
Thus, British group of Harden et al [97] studied 100 Caucasian
patients with IgA nephropathy. While no difference was found in
genotype distribution between the IgA patient population and the
control Caucasian population, patients with DD genotype tended
to present at an earlier age (DD, 33; ID, 34; Il, 42 years), and the
rate of progression was significantly worse in patients with DD
than the others. These observations in a Caucasian population
were duplicated in our study on 64 Caucasian patients with IgA
nephropathy living in the United States [631. Moreover, when
patients presenting with the known risk factors of hypertension
and/or heavy proteinuria were excluded, the difference became
even greater. Thus, in the remaining population, the Dl) fre-
quency in patients with stable serum creatinine was 0%, whereas
that in patients with increasing creatinine 60%. All these studies,
therefore, agree with the notion that, while the ACE I/D genotype
does not affect the incidence of IgA nephropathy, the genotype
has an appreciable impact on the progression of the nephropathy;
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D allele and DD genotype promote poor prognosis in patients
with IgA nephropathy.
Marrie et al [98] reported an association between ACE lID
genotype and renal manifestation in diabetes. They determined
the ACE genotype in 62 French Caucasian patients with insulin-
dependent diabetes (IDDM), who had either persistent micro- (30
to 300 mg124 hr) or macroalbuminuria (> 300 mg124 hr). The
genotype frequency distribution was compared with that in 62
diabetic control without mieroalbuminuria. The II genotype was
present only in 4% of IDDM patients with albuminuria, a
frequency significantly lower than that in control IDDM patients
without albuminuria (15%). Similar results have been reported in
a preliminary fashion from Ireland [99] and Austria [100], indi-
cating that DD genotype has a significant association with diabetic
'nephropathy,' although the definition of nephropathy was un-
stated [99] or broadly interpreted to include cases with only
microalbuminuria [100]. Based on a study of Caucasian IDDM
patients residing in Massachusetts, U.S.A., Doria, Warram and
Krolewski [101] reached a conclusion with an additional qualifi-
cation, that is, ACE lID genotype, not singularly, but in conjunc-
tion with the genotype for a second ACE gene polymorphic locus,
contributes to the susceptibility to diabetic nephropathy. Again,
'diabetic nephropathy' in this study included cases with microalbu-
minuria. Contrasting to these reports are studies from Denmark
[102], Germany [103] and the Netherlands [104], collectively
reporting that IDDM or NIDDM patients with albuminuria (> 30
mg/day) had ACE genotype distribution pattern indistinguishable
from that in diabetic patients without albuminuria.
Thus, the literature is inconclusive with regards to the associa-
tion between ACE gene polymorphism and the incidence of
diabetic nephropathy in IDDM, while such association does not
appear to be present in NIDDM. Of note, in IDDM, once
microalbuminuria develops, more than 80% of patients reach the
stage of overt nephropathy and relentless progression to renal
failure [105, 106]. Contrastingly, only a small portion (—20%) of
NIDDM patients with microalbuminuria progress to overt pro-
teinuria [1061. In fact, this albuminuria is frequently caused by
mechanisms other than diabetes [107, 108]. Thus, the stage of
microalbuminuria in NIDDM is often identified as 'incipient
nephropathy' with the intention to distinguish it from clinical
nephropathy, which is directly linked to poor prognosis. Together
with the finding described below that the locus of ACE l/D
polymorphism is associated with the progression of diabetic
nephropathy, therefore, the albuminuria per se in NIDDM is
difficult to consider as a part of progressive process of renal
involvement in this disease.
In any case, while there is little reason to believe that angio-
tensin is involved in the development of nephropathy in diabetes,
IDDM or NIDDM, evidence is abundant from both experimental
animal studies and clinical observations to indicate that angioten-
sin plays a key intermediary role in the progression of diabetic
nephropathy [24, 109—111]. A study [112] was therefore con-
ducted on 168 Japanese patients with nephropathy secondary to
NIE)DM. A significantly higher incidence of DD genotype was
observed in patients with declining versus stable renal function.
Those patients with DD had more than fourfold greater risk of
progression to renal failure. Of interest, DD genotype was not
found among patients with overt proteinuria and concurrently
stable renal function, implying that overt proteinuria in diabetic
patients with DD genotype is incompatible with preservation of
renal function. A series of studies by Jacobson [113], Tarnow [1141
and their colleagues found that although DD genotype alone does
not have a significant impact on the risk of progression of
nephropathy in IDDM, DD genotype, when superimposed on
hypertension, becomes a significant additive risk factor for pro-
gressive nephropathy.
DD genotype was shown in preliminary studies to serve as a
significant risk factor for progressive loss of renal function in
polycystic kidney disease [115] and others [116], as well.
After reaching end-stage renal failure, patients with DD
genotype may be at an increased risk for cardiovascular events
In contrast to results in IgA nephropathy patients discussed
above demonstrating a significant association between ACE l/D
genotype and progression, several studies [117, 1181 have failed to
obtain similar statistically significant associations. In a letter to the
Lancet, Fukushima et al reported a study examining 49 Japanese
IgA nephropathy patients [117]; those who were already on
dialysis at the time of study were included to assess the prognostic
value of ACE l/D genotype. Although no DD genotype was
present among patients with stable creatinine clearance for  10
years, contrasting to 16% found in patients with poor outcome, no
statistical significance was detected (P values not available).
Schmidt et al [118] conducted a larger scale study on 122 patients
with IgA nephropathy collected from German, Australia, Italy
and Austria. Again, patients on dialysis were recruited. The
results of this multinational study were inconclusive as they noted
only "a trend for a higher frequency of DD-homozygotes in the
end-stage renal failure group (P = 0.07)," although the title of the
paper carries a strongly negative tone, "No Association of Con-
verting Enzyme Insertion/Deletion Polymorphism with Immuno-
globulin A Glomerulonephritis" [118].
If the ACE DD genotype is a significant risk factor for
progression in renal diseases, ACE DD genotype is expected to be
found at a disproportionately increased frequency in the pool of
patients who have already reached end-stage renal failure. In-
deed, one study [119] demonstrated that the DD genotype was
significantly more frequent in renal allograft recipients than
donors. Nevertheless, investigations of patients already on dialysis
[103, 118, 120, 121], including the two studies discussed above for
IgA nephropathy [117, 118], failed to find the expected skew in
ACE genotype distribution among these populations. Of course,
limited size of patient populations may account for the ambivalent
conclusions seen in some of these studies [117, 118]. Alternatively,
when one attempts to reconcile all the results, DD genotype
appears to diminish once patients start dialysis, but not after
patients received renal transplantation. This scenario, which
initially appeared unrealistic, has indeed been supported by a
recent analysis [1121 of diabetic patients with end-stage kidneys.
Thus, in pre-dialysis patients and patients already on dialysis
for one year, the frequency of DD genotype was 33% and 30%,
respectively, whereas, in those on dialysis for > one year, the
frequency was significantly less (15%), suggesting that dialysis
patients with DD genotype carry a significantly higher mortality
rate than those with other genotypes, accounting for the progres-
sive decline in DD genotype frequency in this population over
time. Given that cardiovascular disease is the most common cause
of mortality in dialysis patients, and the risk of cardiovascular
disease is increased among individuals with DD genotype in the
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general population, it is tempting to speculate that the observed
diminution of DD genotype frequency in dialysis patients is
attributed to cardiovascular disease, and this risk is increased in
those with the DD genotype. In support of this notion, Ruiz et a!
[122] have shown that DD genotype is strongly associated with
coronary heart disease in NIDDM patients. Obviously, a system-
atic prospective study is required to test the validity of this
speculation.
Polymorphism of angiotensinogen and angiotensin receptor
genes and renal diseases
More recently, investigators have directed their attention to
identifying potential significance of gene polymorphisms of other
components of the renin angiotensin system in renal diseases. All
the data available today in this area are still in preliminary form,
and were coincidentally presented at the same section of the
annual meeting of the American Society of Nephrology held in
San Diego last fall. Among them, those presented by Fogarty et al
[123] were the only one reporting a positive result for these genes.
They genotyped for the angiotensinogen gene M235T polymor-
phism in 184 patients with IDDM and 100 patients with NIDDM
who were from Northern Ireland and found a significantly higher
angiotensinogen TI' genotype (20%) in IDDM patients with
nephropathy versus IDDM without nephropathy (8%), while TT
was found in 8% in general population. This finding is in contrast
to that in NIDDM where no significant (P = 0.14) difference was
found in the latter. Bib et al [104] similarly genotyped 257 Dutch
patients with IDDM followed for > 15 years. In their study, the
angiotensinogen M235T genotype was not associated with the
incidence of microalbuminuria or the patient's requirement for
dialysis treatment [104].
Similarly to those by Fogarty et a! [123], data by Schmidt et al
[124] from in European Caucasians with NIDDM revealed no
significant difference in allele frequency for angiotensinogen M or
T between patients with (albuminuria > 30 mg/24 hr) versus
without nephropathy [124].
Hamaguchi et al [125] and Hunley et al [63] investigated IgA
nephropathy patients from Japanese (N = 53) and U.S.A. popu-
lation (N = 64), respectively, specifically with regard to the role of
angiotensinogen M235T genotype as a potential risk factor for the
progressive loss of renal function. In neither study, the distribu-
tion pattern of angiotensinogen genotype was significantly differ-
ent between those with versus those without progression.
In two studies from Japan and U.S.A., the potential significance
of angiotensin type I receptor A1166C polymorphism was inves-
tigated. Again, the frequency distribution of genotype was not
significantly different between those with versus without progres-
sion [63, 1261. A similar result was obtained by the same investi-
gators in a group of Japanese patients with NIDDM [112]. It is
safe to say at this point that the angiotensin receptor and
angiotensinogen polymorphisms have little overall impact on the
incidence or progression of these nephropathies in the Japanese
population. Other populations have not been studied thus far for
the receptor gene polymorphism. Of note, the potential associa-
tion between AT1 polymorphism and disease has heretofore been
investivated only for the 2.2 kb exon of the AT1, future studies
may reveal existence of functional and/or marker polymorphic loci
in the non-exon portion of the AT1 gene, which may prognosti-
cate disease in the kidney and other relevant organs.
Why doesn't the ACE genotype have a tighter association with
prognosis?
Although ACE and angiotensin are pathophysiologically im-
portant, and the ACE I/D genotype affects ACE level, there are
number of potential reasons that prevent the genotype from
becoming a 100% accurate predictor.
PCR amplification of I allele is less efficient than that of D
allele, leading to some 5% overestimation of the allele frequency
of D and, therefore, the DD genotype frequency [69]. Since such
technical errors affect genotyping of both patients with and
without stable renal function equally, it tends to undermine a true
statistical significance for a relatively small intergroup difference
in allele/genotype frequency [117]. Thus, some negative conclu-
sions discussed above may be reversed if studies are repeated by
using an insert specific PCR primer (Fig. 3). For the D allele to be
confirmed, the PCR amplification using this primer must also
show the lack of an amplifiable template (that is, insert).
Apart from this technical issue, which affects the statistics of
data analysis, there are a several other reasons for the loose
association between the ACE I/D polymorphism and prognosis of
nephropathies. Unlike simple Mendelian disorders, the process of
progression of many renal diseases results from the interaction of
multiple environmental and genetic factors, where each factor
affects not the quality (such as, presence vs. absence of a specific
protein) but only the quantity (such as, large vs. small amount of
a specific protein) of the phenotype in a cumulative fashion. As
illustrated in Figure 5, the ACE activity in the plasma or local
tissues, is determined by a number of factors, including the ACE
I/D genotype. Thus, the ACE I/D polymorphism may govern
variation in the tissue expression of the ACE gene which, in turn,
modulates the plasma level of ACE activity. Alternatively, the
genotype may affect the proteolytic cleavage of ACE or the
expression of the mRNA for the soluble form [127]. Potentially,
therefore, additional factors can interpose between the ACE
polymorphism and plasma/tissue level of ACE. Those additional
factors, in turn, may be under genetic/environmental regulation,
thereby accounting for the substantial overlap of ACE levels
found among the different ACE I/D genotypes. As further shown
in Figure 5, an enhancement in ACE activity is functionally
significant only if it leads to enhanced Ang II level, the biologically
active ligand. In this regard, ACE activity is only one of the
determinants of Ang II level. Other determinants, such as renin
activity and the availability of angiotensinogen, are also under the
influence of other genetic and environmental factors. Finally,
needless to say, Ang Ills still only one of the factors affecting the
progression of renal diseases. Overall, these multiple pathophys-
iologic steps linking the ACE gene and the progression of renal
disease underlie the loose association between the ACE genotype
and the outcome of chronic renal diseases. The existence of a
significant correlation between ACE genotype and progression
discussed above despite these interpositions, then, speaks for a
strong pathophysiological role of the ACE gene in the process of
progression of renal diseases.
Highly relevant in this regard, is the coincidence that the two
entities of glomerulopathy, that is, diabetic and IgA nephropa-
thies [23, 24, 111, 128], in which ACE inhibitors are effective in
attenuating the loss of renal function, are both characteristically
slow in progression. One can assume then that, when other more
powerful pathophysiological mechanisms are imposed, which can
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Fig. 5. Schematic illustration of the relationship
between the ACE gene lID genotype and the risk
of progression of renal diseases. The Figure
illustrates the existence of several intermediary
phenotypes between the two. Tissue ACE
activities, which the ACE genotype is expected
to affect, are under the influence of other
genetic and environmental factors, as are those
intermediary phenotypes, as well as the tertiary
phenotype, that is, progression of renal
diseases. Circulating ACE activities and
manifestation of hypertension are also under
the influence of, among factors, the two
intermediary phenotypes, that is, tissue ACE
activities, and tissue (or secondary circulating)
angiotensin II levels. Because of the
contribution of these multiple factors affecting
each phenotype, the association between ACE
genotype versus progression of renal disease, or
ACE gene versus hypertension becomes less
tight.
trivialize the pathophysiologic contribution of RAS, the renal
deterioration becomes rapidly progressive, and ACE inhibitors
have little deterrent value. Along these lines, a study [129]
examining patients with progressive IgA nephropathy revealed
that although patients with declining renal function as a whole
have significantly higher incidence of ACE DD genotype than
those with stable renal function, a subgroup of patients with
rapidly progressive loss of function does not have such a disequi-
librium in genotype distribution. Thus, DD genotype impact
appears to be trivialized by the presence of other powerful
injurious mechanism(s) in this rapidly progressive subgroup of
patients. The ACE l/D genotype and the progression of renal
disease can dissociate for other reasons as further discussed in the
next section.
Is the ACE gene LID locus functional?
As noted above, a functional consequence of the ACE l/D
genotypes (II, l/D or DD) is difference in the ACE level [61]. A
simple explanation for this is that the 'insert' within the regulatory
region of the ACE gene contains a silencer element, deletion of
which activates the ACE gene although the insert is recognized as
an Alu sequence. Of interest, there is a remarkable DNA se-
quence homology between a 13 base pair within the ACE
insertion fragment and a negative regulatory element (NRE) that
has recently been found in a mouse renin gene, Ren-1 [130]. The
DNA sequence of the Ren-1 NRE is homologous to silencer
elements of other mammalian genes, including the human renin
gene [131], the human c-myc gene [1321, the chick lysozyme gene
[133], the rat collagen II gene [134] and the human T call receptor
gene [135], implying a family of NRE/NRE binding proteins can
regulate expression of a variety of genes [130]. Nevertheless, the
possibility also exists that the ACE lID polymorphism per se lacks
functional significance but, instead, represents a 'marker' for the
variant of another truly functional gene locus that is in close
proximity to the ACE lID locus so that they arc nearly always
inherited together.
If two mutated loci are, instead, physically remote, the mutated
loci will be inherited totally independently by the offspring.
During meiosis a pair of homologous chromosomes of ovum and
sperm origins crossover numerous times, thereby producing a
patchwork assembly of alleles that is unique to the fetus. If two
gene loei of interest are physically distant, the possibility of
crossover between these loci will be high. The probability will then
increase up to 50% that one locus be inherited from the father,
and the other from the mother. In contrast, the same probability
will fall to nearly zero if the two loci are in proximity. The
frequency of recombination between the two loci is largely,
although not solely, determined by the physical distance between
the two loci. The possibility therefore exists that, separate from
the l/D locus, which may by itself not be functional, a truly
functional polymorphic locus exists in proximity to the l/D locus.
The degree of physical distance between these two potential loci
may, thus, explain the degree of looseness in the correlation
between l/D genotype and plasma or tissue ACE activities.
Segregation and linkage analyses in a series of French Cauca-
sian families [127] indicated that 44% of the inter-individual
variability of ACE levels is accounted for by a variance in a
putative major gene, or quantitative trait locus (QTL), while the
ACE l/D polymorphism accounts for only 28%, although both are
at a significant linkage disequilibrium, that is, inherited in a tightly
linked manner. Moreover, the frequency of h (associated with
high ACE level) allele of QTL on D allele was 0.78, that is, less
than 1.0, so that a significant fraction (0.22) of the D alleles were
carrying 1 (associated with low ACE level) alleles. Here, as the
DNA sequence pattern of the QTL locus is not defined, and the
polymorphic pattern is defined only functionally, the two poly-
morphic alleles are depicted as 1 and h alleles. The study suggested
that l/D is an important marker polymorphism for the h/i func-
tional polymorphism as they are physically adjacent on the
genome, and in fact, the QTL is within the ACE gene. Of note, the
relationship between the ACE l/D/locus and QTL may well be
disrupted in ethnically diverse populations, such as those sub-
jected to the negative study by Lindpaintncr et al discussed earlier
[69].
A most recent combined segregation-linkage analysis in a series
of African Caribbean families from Jamaica [136] also demon-
strated that the plasma ACE levels are determined in great part by
genetic factors. Their detailed model-fitting analysis predicted the
existence of two QTL5 within the genome, which affect ACE level
in an additive fashion, one within or close to, and the other remote
Fig. 6. Physical relationship between the ACE
I/D locus and the two quantitative-trait loci
(QTL) Jbr plasma ACE level on the genome as
estimated and documented by McKenzie et al
[136]. Based on the frequencies of the degree
of linkage disequilibrium, one QTL (QTLI) is
estimated to be within slightly less than I
centiMorgan (approximately 1 million
nucleotide-length), while the other (QTL2) is
distant, from the ACE lID locus, most likely on
a different chromosome. We speculate based on
other available data that, if these two functional
loci indeed exist, QTL1 determines the local
tissue ACE level, while QT2 determines the
transfer of tissue ACE into, or the elimination
of ACE from, the plasma.
from (and therefore unlinked with) the ACE gene (Fig. 6).
Furthermore, the pattern of disequilibrium detected by l/D
polymorphism indicated that, although there is a significant
association between ACE I allele and the I allele of the first QTL
(QTL1 in Fig. 6), lID polymorphism locus is not the QTL locusper
se, but rather functions as an informative marker for h/l alleles. It
was concluded that 79% of the total variability of plasma ACE
levels is jointly influenced by these two QTLs. Of the 79%, 52% is
attributed to the QTL that is not linked to ACE l/D locus (QTL2
in Fig. 6). Given the close association between DD genotype and
renal phenotype reported for IgA and diabetic nephropathies,
which is seemingly at odds with the great contribution to plasma
ACE levels of the unrelated QTL, it appears likely that the
unrelated QTL may be involved in the release of ACE from tissue
to plasma or the degradation of plasma ACE (but not tissue ACE
synthesis/degradation), such that the tissue and plasma ACEs are
only loosely associated.
Therapeutic implications of RAS polymorphisms
The various data discussed thus far collectively indicate that the
ACE lID genotype has a significant correlation with tissue ACE
levels and with the outcome of slowly progressive renal diseases.
Within well-defined subgroups of patients, existence of a strong
correlation even allows the ACE lID genotype to serve as a
predictor of their prognosis. it is also true, however, that a
substantial fraction of patients carrying the homozygous II geno-
type also progress to end-stage renal failure. It is reasonable to
attribute the progression of these atypical' patients to a pro-
nounced imposition of other non-ACE genetic and environmental
risk factors. When compared to these atypical patients with poor
prognosis, then, are the typical DD genotype patients with
progressive renal diseases better candidates for the therapeutic
use of ACE inhibitors (ACEi) since ACE may play a significant
pathogenic role in the latter? Or, because of a profound activation
of ACE, is the latter group more resistant to a given dose of ACE
inhibitors? In our study on IgA patients [95], those with DD
genotype had a significantly and profoundly greater reduction in
proteinuria in response to ACEi when compared to those with
other genotypes. Relevant to these observations is the recent
study in diabetic patients by Gansevoort, de Zeeuw and de Jong
[137] demonstrating a strong correlation between the degree of
reduction in proteinuria achieved shortly after starting ACEi
administration and the degree of preservation achieved during a
subsequent long-term period. Thus, the pronounced short-term
antiproteinuric effect of ACEi in IgA nephropathy patients with
DD genotype speaks for the first possibility, and may reflect the
pathophysiological importance of the enhanced ACE activity in
these patients, where ACEi is particularly efficacious for preserv-
ing GFR. In contrast, a preliminary study by Jacobsen et al on
hypertensive IDDM patients [113] is in support of the second
possibility, namely increased tolerance in DD patients to ACEi.
Thus, during treatment with captopril, GFR declined more rap-
idly in their diabetic patients with DD genotype when compared
to those with other genotype patients. It remains to be established
in the IDDM patients, then, whether the observed apparent
absence of captopril's effect on GFR represents art overall ther-
apeutic inefficacy of pharmacological inhibition of ACE, or a
greater dose requirement for ACEi in patients with DD genotype.
In this regard, no dose range has been established for the
renoprotective effect of any ACE inhibitors, as they are effective
even in patients without hypertension [23]. The result of such
studies will have either of the two opposite implications for the
efficacy of ACEI in patients genotyped for ACE polymorphism,
that is, those with DD should be given high ACEi doses, or should
seek therapeutic intervention other than ACEi.
Potential pitfalls in genotyping studies for polymorphism
One of the potential pitfalls in examining the significance of a
polymorphic gene locus has been discussed in the context of
underestimated DD genotype frequency in patients with Ml or on
dialysis. Such an error in sampling populations can, in general,
lead to both under- and overestimation of the frequency of a
specific genotype. The second form of error occurs during geno-
typing, as represented by the underestimation of I allele frequency
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in ACE lID polymorphism discussed earlier. This form of error,
which affects both susceptible and non-susceptible populations,
tends to undermine the significant association existing between
the genotype and phenotypic disease presentation.
Although not mentioned, our lack of knowledge regarding the
precise phenotype, as reflected by the somewhat arbitrary defini-
tion of 'progressive' renal disease in published studies, may also
undermine the chance of detecting a true biological association.
This error in phenotyping, a third form of error, cannot only
under- but also overestimate the significance of relationship
between genotype and phenotype. It is apparent that the search
for gene polymorphic loci that have association with disease
susceptibility heavily counts on the power of statistics since the
direct functional role of the DNA locus is usually not established.
First of all, the impact of the genotype may be subtle and
quantitative rather than marked or qualitative, so that it may be
technically difficult to identify such a direct functional role. Under
this circumstance, statistical analysis may sometimes be mislead-
ing. For example, if a locus for the susceptibility to a certain
disease is searched for in more than 20 polymorphic sites of
gene(s), at least one is expected to be found statistically significant
with P < 0.05. Or, if more than 20 disease entities are investigated
for a given polymorphic DNA locus, this locus may appear to
serve as a significant susceptibility marker for at least one disease.
Even within a population of patients having the same well-defined
disease entity, if patients are grouped into more than 20 different
ways based on the nature of manifestations (such as different cut
points for the rate of reduction in GFR), at least one form of
manifestation will appear to have a significant association with a
specific genotype. Once a statistical analysis reveals a significant
association between a genotype and a disease phenotype, there-
fore, it is critically important that the effort be continued by
investigators to expand the sample population while emplying the
same criteria for defining the specific phenotype. In so doing, a
true biological association is expected to increase, while a false
relationship will decrease the degree of statistical significance.
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